Modern Pediatrics. Ukraine. (2024). 8(144): 129-138. doi: 10.15574/SP.2024.8(144).129138
Nykytyuk S. O.¹, Levenets S. S.¹, Svoboda O. V.¹, Shostak I. Y.^2
1I. Horbachevsky Ternopil National Medical University, Ukraine
²Ternopil Regional Clinical Children Hospital, Ukraine

For citation: Nykytyuk SO, Levenets SS, Svoboda OV, Shostak IY. (2024). Modern approach to the treatment of cystic fibrosis in children. Modern Pediatrics. Ukraine. 8(144): 129-138. doi: 10.15574/SP.2024.8(144).129138.
Article received: Aug 24, 2024. Accepted for publication: Dec 10, 2024.

Cystic fibrosis is the most common monogenic pathology with an autosomal recessive type of inheritance. The frequency of carriers of the cystic fibrosis gene is 3-4%. The disease leads to damage to the respiratory system, pancreas, intestines, gallbladder, and liver, and can lead to electrolyte loss and the development of diabetes mellitus. In Ukraine, 250-300 children with cystic fibrosis are born every year. Their average life expectancy is 13-14 years. As of 2024, there are 16 children with cystic fibrosis in the Ternopil region.
Aim – to analyze and present clinical cases of cystic fibrosis in children, to investigate the features of the course and treatment of cystic fibrosis in children using the example of two clinical cases and to evaluate the effect of the three-component drug Tricaft (ivacaftor + tezacaftor + elexacaftor) on the course of the disease.
Literature search of scientific publications and study of inpatient charts of two patients who were inpatients in the gastroenterology department were conducted.
Clinical cases. The charts of inpatients and genetic confirmation of two patients diagnosed with cystic fibrosis were studied. In the first case, a boy, 12 years old, is treated annually on an outpatient and inpatient basis. It is known that the first patient was treated with the three-component drug Tricaft with the active ingredient elexacaftor, tezacaftor and ivacaftor. The second case is a boy, 16 years old, who did not receive the three-component drug in his treatment. In both cases, a comparative analysis of clinical manifestations was carried out and the course of the disease was assessed.
Conclusions. In children with cystic fibrosis with pancreatic insufficiency, in parallel with the intestinal tract damage, damage to the bronchopulmonary system is noted with varying degrees of severity of functional and clinical manifestations.
Clinical manifestations and complications from the side of the systems of lesions in cystic fibrosis worsen with age.
Taking drugs that moderate the CFTR receptor reduce the severity of clinical symptoms from the side of the bronchopulmonary system in children with cystic fibrosis, which is manifested in violations of the lowest degree of severity of the functions of the cardiovascular and bronchopulmonary systems.
The study was carried out in accordance with the principles of the Declaration of Helsinki. The informed consent of the children's parents was obtained for the research.
No conflict of interests was declared by the authors.
Keywords: cystic fibrosis, children, tricafta, CFTR receptor, genetic disease, sweat chlorides.

REFERENCES

1. Berezenko VS, Reznikov YuP, Krat VV. (2017). Cystic fibrosis in children. Early diagnosis as important predictor of treatment efficiency (clinical case). Perinatologiya i pediatriya. 3(71): 74-80. https://doi.org/10.15574/PP.2017.71.74

2. Boiarchuk OR, Kosovska VO, Kosovska TM. (2019). Osoblyvosti perebihu mukovistsydozu v ditei Ternopilskoi oblasti. Aktualni pytannia pediatrii, akusherstva ta hinekolohii. 1: 5-9. https://doi.org/10.11603/24116-4944.2019.1.10173

3. Guo J, Garratt A., Hill A. (2022). Worldwide rates of diagnosis and effective treatment for cystic fibrosis. Journal of Cystic Fibrosis. 21(3): 456-462. https://doi.org/10.1016/j.jcf.2022.01.009; PMid:35125294

4. MOZ Ukrainy. (2016). Mukovistsydoz. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Nakaz Ministerstva okhorony zdorov'ia Ukrainy vid 15.07.2016 No. 723. URL: https://dec.gov.uа/wp-content/uploаds/imаges/dodаtki/2016_723_Mykoviscidoz/2016_723_YKPMD_Mkvsz.pdf.

5. Ong T, Ramsey BW. (2023). Cystic Fibrosis: A Review. JAMA. 329(21): 1859-1871. https://doi.org/10.1001/jama.2023.8120; PMid:37278811

6. Patel S, Nugent K. (2023, Oct 31). Neutrophil bactericidal activity and host defenses in cystic fibrosis: a narrative review. J Thorac Dis. 15(10): 5773-5783. Epub 2023 Sep 22. https://doi.org/10.21037/jtd-23-846; PMid:37969285 PMCid:PMC10636459

7. Rafeeq MM, Murad HAS. (2017, Apr 27). Cystic fibrosis: current therapeutic targets and future approaches. J Transl Med. 15(1): 84. https://doi.org/10.1186/s12967-017-1193-9; PMid:28449677 PMCid:PMC5408469

8. Schmidt BZ, Haaf JB, Leal T, Noel S. (2016 Sep 21). Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives. Clin Pharmacol. 8: 127-140. https://doi.org/10.2147/CPAA.S100759; PMid:27703398 PMCid:PMC5036583

9. TGA. (2022). TRIKAFTA (Vertex Pharmaceuticals Australia Pty Ltd). URL: https://www.tga.gov.au/resources/prescription-medicines-registrations/trikafta-vertex-pharmaceuticals-australia-pty-ltd-0.

10. Zaher A, ElSaygh J, Elsori D, ElSaygh H, Sanni A. (2021 Jul 3). A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy. Cureus.13(7):e16144. PMID: 34268058. PMCID: PMC8266292. https://doi.org/10.7759/cureus.16144